Apeloa Pharmaceutical vs Charles River Laboratories: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Apeloa Pharmaceutical Co Ltd (000739.CS)

Q3 202616 Jul – 14 Sep 2026

▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.
These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.
Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.
These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.
Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.
This is a new, significant negative financial result that directly impacts valuation and investor confidence.
CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.
This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

August 202616 Jul – 14 Sep 2026

▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.
These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.
Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.
These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.
Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.
This is a new, significant negative financial result that directly impacts valuation and investor confidence.
CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.
This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

Latest16 Jul – 14 Sep 2026

▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.
These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.
Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.
These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.
Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.
This is a new, significant negative financial result that directly impacts valuation and investor confidence.
CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.
This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

Charles River Laboratories (CRL)

Q3 202618 Jun – 21 Aug 2026

▲4

CRL's biotech recovery and AI deals drive 89% rally

AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.
New collaboration that expands demand and technology positioning, directly driving future revenue.
Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.
Analyst upgrade reflects improving fundamentals and boosts investor sentiment.
Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.
Earnings beat and guidance raise confirm operational turnaround, a key price driver.
DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.
Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

July 202618 Jun – 21 Aug 2026

▲4

CRL's biotech recovery and AI deals drive 89% rally

AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.
New collaboration that expands demand and technology positioning, directly driving future revenue.
Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.
Analyst upgrade reflects improving fundamentals and boosts investor sentiment.
Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.
Earnings beat and guidance raise confirm operational turnaround, a key price driver.
DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.
Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

Latest18 Jun – 21 Aug 2026

▲4

CRL's biotech recovery and AI deals drive 89% rally

AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.
New collaboration that expands demand and technology positioning, directly driving future revenue.
Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.
Analyst upgrade reflects improving fundamentals and boosts investor sentiment.
Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.
Earnings beat and guidance raise confirm operational turnaround, a key price driver.
DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.
Summarizes the powerful rally and underlying operational improvements that continue to support the stock.